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Th  e syndrome of dementia is greatly feared by many 
people, robbing them of their dignity, independence and 
ability to lead a meaningful life – at least on the terms set 
by their predementia selves. Th  e diagnosis of dementia 
can be diﬃ     cult, especially for nonexperts. First, the 
syn  drome of dementia needs to be distinguished from 
somewhat less onerous diagnoses, such as deafness, 
depression and delirium. Next, when the dementia is 
established, its cause needs to be sought out.
In practice, the syndromic diagnosis is more compli-
cated still – even for experts – because it is common to 
identify people who have veriﬁ  able memory symptoms, 
and sometimes even mild decline in one of two other 
cognitive domains. What can be especially tricky is that 
many such people appear not (yet) to have reached a 
threshold of functional impairment that would allow a 
dementia diagnosis to be made with conﬁ  dence.  Th  is 
state of cognitive impairment without important cogni-
tive decline is best known as mild cognitive impairment. 
Of some interest is the fact that this state places the 
person so aﬀ  ected at much higher (but not certain) risk 
for developing unequivocal dementia. For these reasons – 
diagnostic uncertainty, the need to distinguish, early on, 
those at greatest risk, and (as discussed below) the need 
to monitor treatment eﬀ  ects – much eﬀ  ort is now being 
devoted to developing and validating so-called bio-
markers. But how reasonable is it that biomarkers will 
meet these important challenges?
Biomarker is the term given to ‘measurable biological 
characteristics that can either serve as indicators of 
normal or pathogenic processes in the body, or as tools to 
track pharmacological responses to therapeutic drugs’ 
[1]. Th  eir validation in dementia is inspiring an enthu-
siasm that seems imprudent to many people, because it 
glosses an essential aspect of how to test tests.
Validity can be understood in many ways, but a trini-
tarian approach of content, construct and criterion validity 
is well accepted [2]. Content validity refers to whether a 
test stands to reason; its assessment is largely qualitative. 
Construct validity assesses whether a candidate measure 
correlates with like measures, and not with unlike 
measures. Criterion validity has two components – the 
ability to predict outcomes (tested here in forecasting 
disease progression, or the response to treatment) and 
validation against a referent, which in medicine is often 
referred to as validation against a diagnostic gold standard.
Th   e problem is not just that we have no gold standard 
in dementia; the problem is that even were we able to 
Abstract
As Alzheimer’s disease remains a clinical diagnosis, and 
as clinical diagnosis can be diffi   cult, it makes sense to 
look for so-called biomarkers. A biomarker predicts 
who is likely to have the illness and who is not. Some 
biomarkers might even correlate with a clinically 
meaningful response to treatment. Developing 
biomarkers is often characterized as searching for a 
diagnostic gold standard that can seem appealing 
in its promise of certainty. Even so, considering both 
the economic history of the gold standard and the 
results of neuropathological studies, framing the search 
for measurable, biological correlates of dementia 
syndromes in this way is likely to be self-defeating. 
Instead of considering biomarkers as providing 
certainty through referent criterion validation, currently 
it makes more sense to test their construct validity 
and their predictive ability. This means that while 
biomarkers should inform, they will not dictate clinical 
meaningfulness. For the foreseeable future, even were 
they to inform diagnosis, biomarkers cannot substitute 
for understanding whether patients and caregivers fi  nd 
a given dementia treatment eff  ective. Instead, clinicians 
should recognize their own determining role, both in 
dementia diagnosis and in the evaluation of treatment. 
These roles will best be executed by hearing what 
patients and caregivers tell us about dementia, and its 
response to treatment.
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process for diagnostic purposes, it is unlikely to meet the 
level of near-magical thinking needed now required to 
accept a test as a gold standard. Most important, we can 
never have a high level of certainty about how biomarkers 
relate to clinical meaningfulness without involving 
patients and caregivers, the very factor that biomarkers 
are aiming to supplant.
Th  e experience with what were long considered gold 
standard dementia biomarkers is salutary. Given their 
long iconic role, many of us believed – if there was some 
way to measure them prior to autopsy – the plaques and 
tangles that are demonstrable by histopathology would 
have allowed what the National Institute of Neurological 
Disorders and Stroke/Alzheimer’s Disease and Related 
Disorders Association diagnostic criteria for Alzheimer’s 
disease (AD) called a ‘deﬁ  nitive’ diagnosis [3]. But those 
criteria date back more than a generation – to 1984 – and 
are beginning to show their age.
Th   e idea of a deﬁ  nitive diagnosis resting on plaque and 
tangle counts has been under erosion since at least the 
1997 Nuns Study report of the mediating role played by 
even single lacunes in disease expression [4]. Amongst 
many reports from the new millennium, the Cognitive 
Function and Ageing Study investigators – who examined 
autopsy cases in a prospective cohort study of older, 
community-dwelling people – found that more people 
aged 85+ had pathological evidence of dementia than had 
clinical evidence of dementia. What is more, no cut-oﬀ   
point of degenerative or ischemic lesions optimized the 
dementia diagnostic accuracy [5]. So if not even neuro-
pathology can oﬀ  er a gold standard diagnosis, perhaps 
the fault is not with the plaques and tangles but with the 
idea of a criterion diagnosis, especially in dynamic bio-
logical systems.
What, then, is (or was) the gold standard? In economic 
history, the term refers to the practice of ﬁ  xing  a 
country’s currency against a speciﬁ  ed amount of gold. 
But history has not been kind to that proposition; 
notwithstanding the current economic upheavals, not 
even the gold standard is a gold standard, an idea in 
which few economists see merit [6]. Indeed, not since 
President Richard Nixon ended the Bretton Woods 
agreement in 1971 has a major world currency used the 
gold standard.
So why does the dementia community persist with 
using a metaphor for an idea long discredited by the 
people who understand it professionally? Beyond inertia, 
and the typical economic naiveté of people in this line of 
work (‘a physician and his money are soon parted’, as the 
ﬁ  nancial planners say) is the potential advantage oﬀ  ered 
to the pharmaceutical industry. At present, pharma must 
contend with comparatively messy clinical interactions to 
know whether their drugs work. Th   eir desire to move to 
what is typically described as the cleaner objective of 
need chieﬂ  y to change a number, preferably one that can 
be obtained with an easy-to-order blood or imaging test, 
is understandable. As a pharma attendee at a recent 
dementia bio  markers meeting put it – ‘we need our own 
cholesterol test’.
Such a test would oﬀ  er many advantages. It would have 
the patina of objectivity, which is often equated to non-
arbitrariness. Th  is test could dramatically reduce the 
dimensionality of dementia, which otherwise requires 
evaluation of cognition, function, behavior, quality of life, 
caregiver burden and costs. But regulators have been 
careful to distinguish between those biomarkers that aid 
in the diagnosis of an illness, and surrogate markers that 
can substitute for a clinically meaningful endpoint, such 
as a measure of how a patient feels, functions or survives 
[7]. To be validated as a surrogate measure, any candidate 
measure for AD must show a unique link to the disease 
pathophysiology, must be speciﬁ   c and sensitive in 
relation to clinically diagnosed dementia, and must be 
able to distinguish degrees of risk in outcomes. Many 
considerations mitigate against any current measure 
meeting these criteria anytime soon. Not least of these 
are the heterogeneity of disease progression in cognitive 
impairment and the tendency for the most common 
dementia phenotypes – late-onset AD in older patients 
with multiple vascular risk factors – to have more than 
one operational cause of their dementia.
Th   e opportunity cost in terms of a better appreciation 
of AD and its treatment is another reason to be skeptical 
about viewing biomarkers as the gold standard. In the 
early days of AD drug trials, evaluation of executive 
function was all but unknown. Caregiver reports that ‘my 
dad is more like himself’ were dismissed as anecdote. 
Twenty years later, while frontal lobe testing had become 
more evident, even replicable patient accounts (‘I feel like 
the fog has lifted/the smoke has cleared/a window has 
been opened/I was standing oﬀ   stage and now I am front 
and centre’) receive short shrift. We are embarking on a 
new era of AD treatment, past the cholinesterase inhibi-
tors. Th   e lesson from that early experience is not just that 
we should use the clock drawing test, but that we should 
listen to what patients and caregivers have to say, with 
the idea that they will have more to teach us about how 
our new treatments work – and with that with how AD, 
and the brain, operates.
Th  e alternative to a gold standard is to accept and 
better prosecute a strategy of combing construct 
validation with criterion validity that focuses on 
predicting important outcomes. Th  is means employing 
more than one class of measure – not just a biomarker, 
but judgment-free tests (such as neuropsychological 
ones) and judgment-based tests (such as clinical 
interviews, and patient and caregiver questionnaires). It 
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retain them beyond some preliminary phase of validation 
for biomarkers. Importantly, it means that the emphasis 
should be on predicting outcomes (especially the 
outcome of predicting whose cognitive disorder is most 
likely to progress, or who is most likely to respond to 
treatment, and how they will respond) as the highest 
standard for all measures. Th   ese are goals worth aiming 
for and, especially in framing the question of what 
constitutes successful treatment and whether that goal is 
being attained, we will ﬁ  nd it easier to get there if we see 
a central role for the experience of patients (and their 
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